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Abstract: Antibiotic resistance is an increasing public health concern around the world. Rapid 
increase in the emergence of multidrug-resistant bacteria has been the target of extensive research 
efforts to develop a novel class of antibiotics. Antimicrobial peptides (AMPs) are small cationic 
amphiphilic peptides, which play an important role in the defense against bacterial infections 
through disruption of their membranes. They have been regarded as a potential source of future 
antibiotics, owing to a remarkable set of advantageous properties such as broad-spectrum activity, 
and they do not readily induce drug-resistance. However, AMPs have some intrinsic drawbacks, 
such as susceptibility to enzymatic degradation, toxicity, and high production cost. Currently, 
a new class of AMPs termed “peptidomimetics” have been developed, which can mimic the 
bactericidal mechanism of AMPs, while being stable to enzymatic degradation and displaying 
potent activity against multidrug-resistant bacteria. This review will focus on current findings of 
antimicrobial peptidomimetics. The potential future directions in the development of more potent 
analogs of peptidomimetics as a new generation of antimicrobial agents are also presented.
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Introduction
The growing resistance of pathogens is one of the biggest public problems worldwide.1 
Multidrug-resistant bacterial strains can cause severe infections as they are no longer 
responsive to most conventional antibiotics.2,3 To combat these pathogens, efforts 
have been extended to develop a new generation of antibiotics. Antimicrobial peptides 
(AMPs), also termed “host defense peptides” for their immunomodulatory properties, 
are cationic amphiphilic peptides, which are the first line of defense to protect organ-
isms from microbial infection.4–8
It has been demonstrated that naturally occurring or synthetic AMPs can be a new 
functional class of antibiotics.9,10 AMPs are antimicrobial agents based on their activity 
against the prokaryotic membrane. These agents adopt globally amphipathic conforma-
tions upon initial contact with bacterial membranes rich in anionic phospholipids. The 
conformations, which resemble detergent-induced micelle formation, result in total 
membrane disintegration in which their cationic and hydrophobic side groups segregate 
into distinct regions. This finding indicates that AMPs are potential antibiotic agents 
with a different antimicrobial mechanism, and that this activity mainly depends on their 
physical mechanism.11 The structural and sequence diversity of AMPs include amphip-
athic α-helices (eg, cathelicidins), β-sheets with 2–4 disulfide bridges (β defensins and 
protegrins), extended conformation (indolicidin), and beta-loop peptides (brevinin).12–15 
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innate and acquired immunities (Figure 1).8 Importantly, 
AMPs are therapeutic agents with a lower tendency to elicit 
antibiotic resistance than conventional antibiotics.
Currently, the main reasons for the limited practical 
application of AMPs include their very high susceptibility 
to proteolytic degradation by microbial enzymes, toxicity 
due to high amounts of drug needed for therapy, relatively 
short half-life, and their high production cost.16 The design 
and synthesis of peptide mimics (peptidomimetics) have 
been developed to mimic the structure, function, and mode 
of action of host-defense AMPs, which act on bacterial cell 
walls or membranes and can potentially circumvent those 
obstacles. Antimicrobial peptidomimetics display antibacte-
rial activity against a broad-spectrum of bacteria, including 
drug-resistant strains, and are less susceptible to resistance 
development in bacteria. A number of antimicrobial pepti-
domimetics have been developed in the last decade, such as 
β-peptides,17–19 peptoids,20–25 arylamide oligomers,26,27 and 
β-turn mimetics.28,29 Recently, a new class of antimicrobial 
peptidomimetics termed “AApeptides” because they contain 
N-acylated-N-aminoethyl amino acid units derived from 
chiral peptide nucleic acid backbones have been developed. 
They are highly resistant to proteolytic degradation and 
their amphipathic structures can mimic the bactericidal 
mechanism of AMPs.30–32 Currently, different antimicrobial 
AApeptides have been developed, such as α-AApeptides 
and γ-AApeptides.33,34
This review aims to describe recent progress in the dis-
covery of peptidomimetics as new generation antimicrobial 
agents and discusses future directions for antimicrobial 
peptidomimetics in the emergence of multidrug-resistant 
bacteria.
Molecular design and antibiotic 
activity of antimicrobial 
peptidomimetics
To improve the antimicrobial activity of peptidomimet-
ics, the relationship between the structure and function 
of these peptides must be considered. Interestingly, anti-
microbial peptidomimetics may be designed by joining 
amphiphilic peptide building blocks. In this regard, a potent 
and broad-spectrum antimicrobial activity can be fine-tuned 
by changing the ratio of cationic/hydrophobic groups via 
the introduction of hydrophobic building blocks, suggest-
ing that the structure–activity relationships in antimicrobial 
peptidomimetics indicate the balance of forces required 
Human alpha defensin 1 Human beta defensin 1
Human cathelicidin LL-37
2
1
Figure 1 Three-dimensional structures of human antimicrobial peptides.
Notes: The Protein Data Bank identification for these structures are 3GNY for dimeric crystal structure of human α-defensin 1 (or human neutrophil peptide-1); 1e4S for 
human beta defensin 1; and 2K6O for human cathelicidin LL-37 in complex with sodium dodecyl sulfate micelles. Structural coordinates were obtained from the Research 
Collaboratory for Structural Bioinformatics Protein Databank (http://www.rcsb.org). The significance of ‘1’ and ‘2’is for dimeric crystal structure of human α-defensin 1 (two 
peptides: ‘1’ and ‘2’, together).Infection and Drug Resistance 2014:7 submit your manuscript | www.dovepress.com
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for bactericidal activity.35–38 To date, peptidomimetics have 
been designed by cyclization of linear peptides or coupling 
of stable unnatural amino acids. In addition, Hu et al,30 and 
Niu et al31,32 reported the development of a new class of 
peptidomimetics termed “AApeptides”, and depending on 
the position of the side chain (connected to either the α-C or 
γ-C in relation to the carbonyl group), two subclasses of these 
peptides (α-AApeptides and γ-AApeptides, respectively) 
have been designed (Figure 2). Previous studies have indi-
cated that focused libraries of linear AApeptide (including 
both α-AApeptides and γ-AApeptides) sequences have been 
developed so that these sequences might mimic natural linear 
AMPs and adopt globally amphipathic conformations upon 
initial contact with bacterial membranes.39,40 Moreover, it 
has been reported that the antimicrobial activity of some 
AApeptides is still generally comparable, or even supe-
rior, to the AMP magainin as well as a previously reported 
linear α-AApeptide α1 against several bacterial strains.31 
Interestingly, Padhee et al39 reported that a focused library 
of different linear α-AApeptide sequences such as α1 and 
α2 has been prepared to minimize the hemolytic activity, but 
with a potent and broad-spectrum antimicrobial activity to 
arrest the growth of both Gram-positive and Gram-negative 
bacterial pathogens. In addition, these authors showed that 
α1 and α2 are the most potent antimicrobial α-AApeptide 
peptidomimetics with broad-spectrum activity, especially 
toward clinically relevant strains including the multidrug-
resistant strains vancomycin-resistant Enterococcus faecalis 
and methicillin-resistant Staphylococcus aureus (MRSA).39 
Furthermore, a focused library of linear γ-AApeptide 
sequences containing γ-1, γ-2, γ-3, and γ-4 has been 
prepared.40 In this context, it has also been demonstrated 
that compared with γ-1, γ-2 and γ-3, γ-4 contains enhanced 
bactericidal activity against Gram-positive strains, indicat-
ing that some γ-AApeptides are very potent and supporting 
their potential development as antimicrobial agents to treat 
Gram-positive bacterial infections.40 However, they are quite 
toxic to blood cells as well as other mammalian cells. In 
fact, the antimicrobial activity of γ-AApeptides is likely to 
be enhanced if the overall hydrophobicity increases, which 
at the same time also leads to increased hemolytic activity 
and cytotoxicity. Interestingly, the hemolytic activity and 
cytotoxicity can be minimized by introducing more cationic 
residues.
On the other hand, focused libraries of lipo   AApeptides 
(including both α-AApeptides and γ-AApeptides) sequences 
have been developed, and the lipid tails of these lipo-
peptides are important for biological activity to facilitate 
bacterial membrane interaction, giving them broad-  spectrum 
activity against both Gram-positive and Gram-negative 
bacteria.30,31 A focused library of lipo antimicrobial 
α-AApeptides sequences has been prepared, including α3 and 
α4.32   Interestingly, the development of cyclic γ-AApeptides 
that mimic function of AMPs has been reported.41 These 
cyclic peptides have enhanced antimicrobial activity 
compared with their linear antimicrobial AApeptides, as 
their   structures adopt a semirigid backbone conformation, 
resulting in a more stable amphipathic structure. Structure–
activity relationships of cyclic antimicrobial γ-AApeptides 
incorporating a global distribution of cationic and hydro-
phobic residues are in   development. In this context, group 
amphiphilic building blocks can be joined, and the resulting 
oligomers are cyclized.42
Since peptidomimetics interact nonspecifically with their 
target membranes, the addition of a positive charge by adding 
arginine, lysine, or histidine residues to the peptide sequence 
is required for initial electrostatic attraction with negatively 
charged bacterial membranes, whereas hydrophobic bulk 
guides insertion into the bacterial membrane. In addition, 
increasing hydrophobicity may increase antimicrobial 
activity. Recent developments in peptidomimetics that are 
formed through insertion into the amino acid backbone or 
heteroatom replacement indicate that several peptidomimet-
ics form structural designs such as helices, sheets, turns, and 
loops via noncovalent interactions. To prepare AApeptides, 
the current literature indicates that different approaches have 
been developed.32,43 Originally, the synthesis of these peptides 
was achieved using the building block strategy (Figure 3).30–32 
In this approach, 9-fluorenylmethyloxycarbonyl-protected 
peptide building blocks were prepared and then assembled on 
a solid support to provide the desired peptide sequences.44–47 
Another approach termed “submonomeric” has been devel-
oped to prepare γ-AApeptides. This approach is a solid-phase 
synthesis of the peptides, which eliminates the need of build-
ing block preparation; thus, chemically diverse functional 
groups can be conveniently introduced into the desired 
peptide sequences.43
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At present, it has also been reported that preorganized 
secondary structures including helical or sheet-like con-
formations within peptidomimetics are unnecessary in the 
antibacterial activities of these peptides.39,40,48–50 In contrast, 
the presence of backbones with certain flexibility can lead 
to a potent and broad-spectrum antimicrobial activity, indi-
cating the importance of the conformational rigidity in the 
molecular design of antimicrobial peptidomimetics.51–53 In 
this context, peptidomimetics have more dihedral angles 
compared to canonical peptides, and this molecular design 
induces high flexibility.
Previous studies have indicated that in the molecu-
lar design of the amphipathic helical 21-mer peptide 
([KAAKKAA]3; amino acid sequence: K A A K K A A 
K A A K K A A K A A K K A A), the peptide’s cytotoxic 
activity is highly dependent upon the spatial positions of 
tryptophan and cationic residues within the hydrophobic 
sector of an α-helix.54 More recently, the synthesis of enzy-
matically resistant versions of AMPs by partial substitution 
of L-residues with nonnatural D- or B-residues has been 
developed. In this regard, McGrath et al55 synthesized a 
lysine-leucine or klotho peptide known as (KLAKLAK)2, 
which had low toxicity toward mammalian cells, with high 
antimicrobial activity. Furthermore, these authors demon-
strated that D(KLAKLAK)2, a variant of this molecule, is 
bactericidal against several Gram-negative species, including 
Escherichia coli, Klebsiella pneumoniae, and Acinetobacter 
baumannii. Interestingly, a strain of K. pneumoniae, which 
was resistant to conventional antibiotics, was susceptible 
to this peptide with the minimal inhibitory concentration 
of 75 µg/mL. In addition, this peptide has stronger fungi-
cidal activity.55
In the remainder of this review, the discussion will high-
light the discoveries that have led to our current understanding 
of the development of peptidomimetics in the context of their 
use as therapeutic agents.
Therapeutic potential  
of antimicrobial peptidomimetics
Peptidomimetics represent an important field in pharmacol-
ogy as they circumvent the limitations of AMPs used in 
therapy. Therapeutic applications of antimicrobial peptido-
mimetics have also been considered in regard to their high 
resistance against enzymatic degradation.56–59   Regarding 
antimicrobial peptidomimetics which are currently in Phase II 
clinical trials, Choi et al60 have designed small arylamide 
foldamers that mimic AMPs. Importantly, these authors 
also demonstrated that hydrogen-bonded restraints in the 
structure of arylamide increase activity toward S. aureus and 
E. coli. On the other hand, the pharmaceutical company Lytix 
Biopharma AS (Tromsø, Norway) has recently commenced 
Phase I/IIa clinical trials with another antimicrobial peptido-
mimetic known as Lytixar TM (also known as LTX-109) for 
nasal decolonization of MRSA (http://www.lytixbiopharma.
com). This peptidomimetic, containing a modified trypto-
phan derivate as lipophilic bulk, displayed a combination 
of high   antibacterial activity against   methicillin-resistant 
  Staphylococci and staphylococcal biofilms.57 Another 
antimicrobial peptidomimetic, which is currently in Phase II 
clinical trials for the broad spectrum treatment of MRSA 
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Figure 3 General building block strategy for the synthesis of AApeptides.
Notes: each coupling cycle includes an Fmoc deprotection using 20% piperidine in DMF and coupling of α-AA or γ-AApeptides building blocks onto resin in the presence of 
DIC/ODhbt in DMF. After desired sequences are assembled, they are cleaved.
Abbreviations: DIC, diisopropylcarbodiimide; DMF, dimethyl fluoride; Fmoc, 9- fluorenylmethyloxycarbonyl; ODhbt, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine; 
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infections, is   brilacidin (also known as PMX-30063).61 This 
peptidomimetic was synthesized by PolyMedix (Radnor, PA, 
USA) and was then acquired by Cellceutix (Beverly, MA, 
USA) in September 2013. It is important to consider that this 
peptide is a potent bactericidal with broad-spectrum activity, 
not only against Gram-positive bacteria such as S. aureus and 
Enterococcus faecium but also against Gram-negative species 
such as E. coli. Interestingly, in a Phase II study involving 
patients with acute skin infections, 215 patients were treated 
with three different doses of brilacidin, and brilacidin’s favor-
able profile was noted in 65%–87% of patients.61 Another 
antimicrobial peptidomimetic known as POL7080 has also 
been developed. POL7080 is active in the nanomolar range 
against Gram-negative Pseudomonas spp. Researchers at 
the University of Zurich and Polyphor Ltd (Allschwill, 
Switzerland) have developed this peptidomimetic by means 
of a novel approach to peptide preparation named protein 
epitope mimetic technology. This peptidomimetic specifically 
targets Pseudomonas aeruginosa through a mode of action 
that is different from the membrane-disrupting activity of the 
parent compound.29 Currently, POL7080 is being prepared 
by the company Polyphor, and in preclinical studies, this 
antimicrobial peptidomimetic was highly active on a broad 
panel of clinical isolates, including multidrug resistant 
Pseudomonas bacteria, with a potent bactericidal activity in a 
mouse septicemia infection model. P . aeruginosa is an oppor-
tunistic bacteria which causes serious infections in patients 
with reduced immune systems (eg, those having acquired 
immunodeficiency syndrome or cancer). At present, Phase I 
clinical studies29 of the peptidomimetic POL7080 have been 
completed in healthy individuals in Europe, demonstrating 
the clinical safety and tolerability of this peptide (http://www.
polyphor.com/products/pol7080). 
Regarding an important role of antimicrobial peptidomi-
metics in the prevention of virus infections and the treatment 
of cancer metastasis, antimicrobial peptidomimetics that 
inhibit virus replication as well as possess antitumor activ-
ity against different cancer cell lines have been designed. 
Importantly, the structure of these peptidomimetics has been 
explored by using a peptidomimetic library in order to obtain 
higher plasma and metabolic stabilities.   Furthermore, the 
use of nanotechnology as delivery tool for both classes of 
peptides will be presented later in the review. As shown in 
previous reports, some γ-AApeptides are effective in arrest-
ing the growth of both Gram-positive and Gram-negative 
drug-resistant bacterial pathogens.50 In addition, it has been 
demonstrated that γ-AApeptides can mimic the human 
immunodeficiency virus (HIV) Tat peptide by binding to 
HIV-1 RNA with a high affinity, comparable to their peptide 
counterparts.44,46 Moreover, it is well known that the CXC 
chemokine receptor 4 (CXCR4) is a coreceptor of HIV-1 
infection in human cells.62,63 In this context, development of 
peptidomimetic ligands for CXCR4 as therapeutic agents 
for HIV-1 infection and cancer has been reported.64–66 In 
fact, the peptidomimetic Arg(*)-Arg-Nal(2)-Cys(1x)-Tyr-
Gln-Lys-(d-Pro)-Pro-Tyr-Arg-Cit-Cys(1x)-Arg-Gly-(d-Pro)
(*) (POL3026) is a novel specific beta-hairpin mimetic 
CXCR4 antagonist, with potent anti-HIV activity.67 This 
peptide has a ten-fold increase in potency, with a good bio-
availability profile following subcutaneous administration.67 
Interestingly, ligand binding site mapping using a panel of 
CXCR4 mutants demonstrated that the new analog D(1-10)-
vMIP-II-(9-68)-SDF-1 (RCP222) share the interactive 
amino acids on CXCR4 with HIV-1 glycoprotein 120.68,69 
To date, peptidomimetic ligands have served as inhibitors of 
stromal cell-derived factor-1 since these peptidomimetics are 
involved in the interactions of HIV-1 envelope glycoprotein 
and stromal cell-derived factor-1 with membrane ligands of 
CD4+ human cells.70–74 Another peptide with anti-HIV activ-
ity is ALX40-4C. The structure of this peptide was designed 
from the basic HIV-1 transactivation domain for the inhibition 
of Tat–TAR interaction.75 The anti-HIV effects of this peptide 
are elicited through selective binding to CXCR4.76 In addi-
tion, Zhou et al77 reported that the human APJ, a G protein-
coupled seven-transmembrane receptor, is essential for its 
coreceptor activity for HIV-1; thus, it is an alternative target 
of ALX40-4C to block HIV glycoprotein 120 from binding 
to the cellular membrane. On the other hand, regarding the 
development and improvement of nanoparticles for stabiliza-
tion and delivery of antiviral peptides, a nanoformulation of 
the amphiphatic α-helical peptide p41 (a positively-charged 
analog of C5A peptide, derived from the hepatitis C virus 
protein) has been designed to treat HIV/hepatitis C virus 
coinfection, indicating the potential of this nanoformulation 
for stabilization and delivery of antiviral peptides, while 
maintaining their functional activity.78
Currently, cancer is a major concern in relation to human 
mortality, and all types of cancer are characterized by irregu-
lar cell growth. Antitumor drugs are subject to differences 
in target tissue and absorption, which can be particular to 
each patient. In addition, acquired drug resistance is con-
sidered the widespread cause for tumor recurrence.79 At 
present, some radiolabeled γ-AApeptides have been used 
as tracers for positron emission tomography, indicating a 
therapeutic application as anticancer agents.45 In addition, 
peptidomimetics have been the basis for a number of studies Infection and Drug Resistance 2014:7 submit your manuscript | www.dovepress.com
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performed to discover new novel anticancer agents.79,80 In 
this regard, the in vivo inhibitory effects on the growth of 
tumor cell xenografts in nude mice by the cyclic pentapeptide 
FC092 ([D-Arg2]-FC131), a CXCR4 antagonist, have been 
reported.81,82 The intrinsic relationship between its structure 
and its high specificity to tumor cells is likely playing the 
key role in the cytotoxicity of peptidomimetics. These char-
acteristics allow the peptidomimetics to bind to cancer cells 
and disrupt the negatively-charged tumor cell membrane, 
which is derived from a greater than normal expression of 
anionic molecules such as sialic acid-rich glycoproteins or 
phosphatidylserine.83 Importantly, these chemical differences 
aid the electrostatic interaction of the positively-charged 
peptide and the negatively-charged tumor cell membranes.80 
Studies have reported of AMPs that are effective against 
bacteria and cancer cells but not against normal mammalian 
cells such as cecropins from insects and magainins from 
amphibians.84,85 On the other hand, signal transducer and 
activator of transcription (STAT) proteins are a family of 
cytoplasmic transcription factors. Phosphorylation induces 
their homo- or heterodimerization, and an important func-
tion of these dimers is to control gene expression. STAT3 is 
frequently activated in many human cancer cell lines and is 
involved in cancer development and progression. Importantly, 
dysregulation of STAT3 can lead to increase in its activity 
and contribute to tumorigenesis. Currently, peptidomimet-
ics have been utilized to directly target STAT3 signaling. 
In this regard, it has been reported that an oxazole-based 
small-molecule STAT3 inhibitor, which modulates STAT3 
stability, induces significant antitumor cellular effects.86 
One primary goal of drug delivery for cancer therapy is to 
increase the amount of drug delivered to the tumor site and 
decrease its exposure to healthy tissues.87 Recent advances in 
microencapsulation technologies have been used to enhance 
drug protectivity, availability, and distribution by employing 
different biodegradable delivery platforms like liposomes, 
dendrimers, nanoemulsions, polymeric nanocarriers, and 
nanoparticles. These nanoformulations can be used to control 
drug/molecule release and enhance targeted delivery and 
effectiveness.88 In this regard, Wang and Zhang89 encapsu-
lated a polypeptide isolated from the unicellular green algae 
Chlorella pyrenoidosa, which exhibited the highest inhibitory 
activity on human liver HepG2 cancer cells (49%), and they 
named the polypeptide Chlorella pyrenoidosa antitumor 
polypeptide. The main mechanism of action of this peptido-
mimetic is condensation/  fragmentation of nuclear chroma-
tin.89 The in vitro release of this peptide against gastric cancer 
cells   provided a basis for the   development of encapsulated 
  antitumor peptides. The peptidomimetics KLAKLAKKLAK-
LAK and the isoAsp-Gly-Arg (or isoDGR) peptides serve 
as potent tools for developing new antitumor peptides. They 
can selectively kill CD13−/αvβ3+ breast cancer cells in both in 
vitro and in vivo experiments by inhibiting angiogenesis by 
binding to αvβ3+, which is increased on tumor cells.90 Cur-
rently, the antitumor role of the analgesic-antitumor peptide 
(AGAP) isolated from the scorpion Buthus martensii has been 
reported. This protein, consisting of a small ubiquitin-related 
modifier linked with a hexahistidine tag from E. coli, was 
used as an antitumor peptide, and the main mechanism of 
action of this peptidomimetic is through cell cycle arrest.91 
The recombinant system AGAP showed considerable inhibi-
tion of lymphoma and glioma propagation.91 Interestingly, 
using SW480 human colon cancer cells, it was proposed that 
recombinant AGAP induces cell cycle arrest in the G0/G1 
phase, attended by the decrease in the S phase without sig-
nificant change in the G2/M phase.91 Together, these studies 
strongly suggest that the use of peptidomimetics is a potent 
tool for developing new antitumor peptides. The main limita-
tions in the use of these peptides are their poor bioavailability 
due to insolubility related to their intrinsic physicochemical 
properties, potential toxicity to host cells, tissue distribution, 
and poor pharmacokinetic issues. Despite these disadvan-
tages, antitumor peptidomimetics have potential due to their 
high potency and specificity against malignant cells.
It is important to consider that further studies are needed 
to investigate the cost of large scale production of peptidomi-
metics and the transition of these peptides from the laboratory 
to the clinic to confirm that they provide an effective new 
class of therapeutic agents. However, the combination of the 
therapeutic use of peptidomimetics and conventional therapy 
against cancer (eg, chemotherapy, radiotherapy, or surgical 
procedures) can help in overcoming drug resistance in cancer 
cells. Increased funding and innovative research approaches 
to prepare peptidomimetics are required for practical use of 
these peptides as therapeutic agents.
Future directions for 
peptidomimetics research as a new 
generation of antimicrobial agents
Substantial progress has been achieved in the past decade 
with respect to the development of antimicrobial peptido-
mimetics that mimic the bactericidal activity and mode of 
action of AMPs. Since several classes of peptidomimetics 
have great potential as a new generation of antimicrobial 
agents due to their low immunogenicity and enhanced sta-
bility   compared with AMPs, in the near future, it will be Infection and Drug Resistance 2014:7 submit your manuscript | www.dovepress.com
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important to resolve issues of hemolytic activity and cyto-
toxicity of some antimicrobial peptidomimetics. Elucidating 
these concerns will ensure their future application in vivo. 
In this regard, the use of more cationic charges is likely to 
decrease toxicity. It will also be possible to gain further 
insight into the development of molecular design in pepti-
domimetics and to explore its medical and pharmacological 
applications. In fact, fine-tuning the biological activity of 
peptidomimetics may be readily achieved with the introduc-
tion of a variety of additional hydrophobic building blocks. 
In addition, mechanistic studies are needed to evaluate the 
possibility for antimicrobial peptidomimetics to induce 
drug resistance in bacteria, and research will be focused on 
the development of antimicrobial peptidomimetics against 
Gram-negative bacteria, as they are generally more difficult 
to kill than Gram-positive bacteria. Finally, an important chal-
lenge over the next decade will be to develop new potential 
drug delivery systems for peptidomimetics. In this context, 
nanoformulation approaches have emerged as an important 
tool to improve the delivery and stability of antimicrobial 
peptidomimetics.
In conclusion, peptidomimetics possess significant prop-
erties that support their inclusion in the generation of new 
antimicrobial agents. These antimicrobial molecules show 
potent bactericidal activity against drug-resistant bacterial 
strains. Moreover, antimicrobial peptidomimetics have 
several advantages over AMPs, including enhanced stabil-
ity, cell specificity, and better tolerability. Furthermore, the 
synthetic flexibility of these molecules allows fast structure 
modifications to create novel antimicrobial peptidomimet-
ics, having particular pharmacological properties. Finally, 
structure–activity relationships clear the way to establish 
peptidomimetic libraries, which can lead to the development 
of novel antimicrobial agents. A better understanding of the 
structural properties of peptidomimetics will potentially 
facilitate the practical use of these peptides as important 
therapeutic agents.
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